ORPHA:15
Achondroplasia
Publications
7,153
Trials
28
Interventional, condition-specific
Researchers
1,078
Distinct authors in sample
Gene link
FGFR3
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A primary bone with micromelia characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007037
- MeSH:D000130
- OMIM:100800
- UMLS:C0001080
- NCIT:C34345
Additional Mondo synonyms (2)
ACH · achondroplasia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — FGFR3
- LiteraturePresent
7,153 matched papers (2,897 in last 10 years) Source
- Phenotype characterisedPresent
84 HPO annotations (e.g. Bowing of the legs; Disproportionate short stature; Thoracolumbar kyphosis) Source
- Animal modelPresent
20 genotype models (Mus musculus) Source
- Orphan designationPartial
5 EMA designations (none yet with FDA orphan-indication approval) — e.g. C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker Source
- Interventional trialPresent
28 matched on ClinicalTrials.gov (9 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FGFR3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
84
Associated phenotypes · MONDO:0007037
- Bowing of the legs
- Disproportionate short stature
- Thoracolumbar kyphosis
- Macrocephaly
- Brachydactyly
Showing 5 of 84 — open Monarch for the full list.
Animal models (Monarch / Alliance)
20
Model associations linked to this Mondo ID
- Npr2cn/Npr2cn [background:] involves: AKR/J·MGI:3828048·Mus musculus
- Tg(Col2a1-Fgfr3/GH)BDor/0 [background:] FVB/N-Tg(Col2a1-Fgfr3/GH)BDor·MGI:5632165·Mus musculus
- Acancmd/Acancmd [background:] involves: STOCK T tlow Itpr3tf·MGI:3694235·Mus musculus
- Fgfr3tm3.1Cxd/Fgfr3tm3.1Cxd [background:] involves: 129S6/SvEvTac·MGI:3640338·Mus musculus
- Fgfr3tm1.1(FGFR3*)Ytc/Fgfr3tm1.1(FGFR3*)Ytc [background:] involves: 129·MGI:6416454·Mus musculus
- Fgfr3tm5.1Cxd/Fgfr3+ [background:] involves: 129S6/SvEvTac·MGI:3640358·Mus musculus
- Tg(FGFR3-G380R)7Aya/Tg(FGFR3-G380R)7Aya [background:] involves: BALB/c * C57BL/6·MGI:6416492·Mus musculus
- Nppclbab/Nppclbab [background:] B6.PL-Nppclbab/GrsrJ·MGI:3707539·Mus musculus
- Fgfr3tm1Llm/Fgfr3+ [background:] involves: 129S2/SvPas·MGI:5551435·Mus musculus
- Fgfr3tm1Cxd/Fgfr3tm1Cxd [background:] involves: 129S6/SvEvTac * NIH Black Swiss·MGI:3586593·Mus musculus
- Npr2cn-3J/Npr2cn-3J [background:] MRL/MpJ-Npr2cn-3J/GrsrJ·MGI:4947978·Mus musculus
- Pthlhtm1Hmk/Pthlhtm1Hmk [background:] either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * C57BL/6)·MGI:3583956·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
5
Designations · no FDA orphan-indication approval yet
- EMA C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linkerTreatment of achondroplasia · 27/07/2020 · PositiveEMA designation
- EMA modified recombinant human C-type natriuretic peptide (Vosoritide) (Voxzogo)Treatment of achondroplasia · 24/01/2013 · PositiveEMA designation
- EMA Humanised monoclonal antibody derivative against fibroblast growth factor receptor 3Treatment of achondroplasia · 21/06/2021 · PositiveEMA designation
- EMA InfigratinibTreatment of achondroplasia · 19/07/2021 · PositiveEMA designation
- EMA soluble recombinant human fibroblast growth factor receptor 3Treatment of achondroplasia · 27/02/2017 · WithdrawnEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0007037
- INFIGRATINIB·phase 3
- LONAPEGSOMATROPIN·phase 2
- RECIFERCEPT·phase 2
- NAVEPEGRITIDE·phase 2 3
- SOMATROPIN·unknown
- VOSORITIDE·approval
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
7,153
7,153 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
7,153 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,897 in the last 10 years · low confidence
Phrase hits: 7,152 · MeSH hits: 0
Who's working on it?
1,078
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02
- 03Savarirayan R13 papers · 2026
Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia. ravi.savarirayan@mcri.edu.au.
Papers in Europe PMC - 04Cormier-Daire V8 papers · 2026
INSERM UMR 1163, Molecular and physiopathological bases of osteochondrodysplasia, Institut IMAGINE, Paris, France; Université Paris Cité, Centre Référence des Maladies Osseuses Constitutionnelles, Hôpital Necker Enfants Malades, Paris, France.
Papers in Europe PMC - 05Hoover-Fong J8 papers · 2026
Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.
Papers in Europe PMC - 06Alves I7 papers · 2026
ANDO Portugal, University of Évora - CHRC, Évora, Portugal. Electronic address: ines.alves@uevora.pt.
Papers in Europe PMC - 07Imagama S7 papers · 2026
Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Papers in Europe PMC - 08Matsushita M7 papers · 2026
Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Papers in Europe PMC - 09
- 10
Clinical research
Is a treatment being tested?
28
interventional trials for this specific condition
28 interventional trials matched this specific condition name; 9 currently recruiting in our sample.
Data as of 11 September 2026
28 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.8th percentile).
low confidence · 95.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
28 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06926491·RECRUITING·Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT05929807·ENROLLING BY INVITATION·A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT06842355·RECRUITING·A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT07169279·RECRUITING·Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT07441876·RECRUITING·Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT05145010·ENROLLING BY INVITATION·Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT07297875·NOT YET RECRUITING·A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT06732895·RECRUITING·A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT06079398·RECRUITING·A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
Observational and natural-history studies
19 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07388966·RECRUITING·Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Not reviewed·Conditions: Achondroplasia · Hypochondroplasia·Matched via name phrase
- NCT05328050·RECRUITING·Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Not reviewed·Conditions: Achondroplasia · Hypochondroplasia·Matched via name phrase
- NCT02597881·RECRUITING·Achondroplasia Natural History Multicenter Clinical Study
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT06168201·RECRUITING·VIrtual STudy in Achondroplasia for the US (VISTA)
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
- NCT07301463·RECRUITING·A Study in Children With Achondroplasia
Not reviewed·Conditions: Achondroplasia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 14 · after dedupe 14 · already on CT.gov 2 · kept 0 · parent 0 · uncertain 12 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (12)
- ctis·2025-523811-12-00·Authorised·A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2024-518072-31-00·Authorised, ongoing·Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2024-515469-32-00·Cancelled·ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period
skipped — LLM skipped (--skip-llm)
- ctis·2024-514208-15-00·Authorised, ongoing·teACH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 years of age) with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2024-513857-55-00·Authorised, ongoing·Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE
skipped — LLM skipped (--skip-llm)
- ctis·2023-508754-26-00·Cancelled·A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2023-508864-31-00·Expired·A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2023-508341-40-00·Expired·COACH: A Phase 2, Open-Label, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2023-506091-27-00·Authorised, recruiting·A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 years of age) with Achondroplasia followed by an Open Label Extension (OLE) period.
skipped — LLM skipped (--skip-llm)
- ctis·2023-506130-67-00·Cancelled·A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
skipped — LLM skipped (--skip-llm)
- ctis·2023-503677-37-00·Cancelled·A Phase 2, open-label, multi-center, 2-stage sequential cohort, dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous SAR442501 in pediatric participants with Achondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2022-502202-33-00·Authorised, ongoing·AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Achondroplasia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Achondroplasia")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Achondroplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 28 interventional · 19 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ACH
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:05:58.292Z
